Publicacións nas que colabora con María Buti Ferret (21)

2024

  1. Characterizing Hepatitis Delta in Spain and the gaps in its management

    Gastroenterologia y Hepatologia

  2. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

2023

  1. Increasing and sustaining blood-borne virus screening in Spain and Portugal throughout the COVID-19 pandemic: a multi-center quality improvement intervention

    Frontiers in public health, Vol. 11, pp. 1268888

  2. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602

  3. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  4. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

  5. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

    Digestive Diseases and Sciences, Vol. 68, Núm. 6, pp. 2731-2737

2021

  1. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review

    Scientific Reports, Vol. 11, Núm. 1

  2. Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure

    Journal of Viral Hepatitis, Vol. 28, Núm. 9, pp. 1319-1324

2020

  1. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study

    Alimentary Pharmacology and Therapeutics, Vol. 52, Núm. 3, pp. 500-512

2019

  1. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs

    Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672

2018

  1. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis

    Gastroenterology, Vol. 155, Núm. 4, pp. 1120-1127.e4

2017

  1. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

    Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311

  2. Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System

    Medicina Clinica, Vol. 148, Núm. 6, pp. 277-282

  3. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection

    Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1

  4. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry

    Hepatology, Vol. 65, Núm. 6, pp. 1810-1822

2016

  1. Altered underlying renal tubular function in patients with chronic hepatitis B receiving nucleos(t)ide analogs in a real-world setting the MENTE study

    Journal of Clinical Gastroenterology, Vol. 50, Núm. 9, pp. 779-789

  2. Randomized controlled trial of the NS5A inhibitor daclatasvir plus pegylated interferon and ribavirin for HCV genotype-4 (COMMAND-4)

    Antiviral Therapy, Vol. 21, Núm. 3, pp. 195-205

2015

  1. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2014

  1. Cost-utility analysis of triple therapy with telaprevir in treatment-naïve hepatitis C patients

    Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria, Vol. 38, Núm. 5, pp. 418-429